Figure 2 | Scientific Reports

Figure 2

From: Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Figure 2The alternative text for this image may have been generated using AI.

PSA response. Waterfall plots depicting best PSA responses in patients starting ARTA treatment according to CTC status, (A, left panel) CTC − patients, (A, right panel) CTC + patients, and AR-V7 status, (B, left panel) AR-V7- patients, (B, right panel) AR-V7 + patients. The dotted line illustrates the threshold of PSA 50% decline defining a PSA response. When comparing patients concerning CTC status, PSA response rates were 8/11 (72.7%) and 23/54 (42.6%) in CTC − and CTC + patients, respectively, without statistical significance (p = 0.10; Fisher’s exact test). PSA response rates were 20/32 (62.5%) and 11/33 (33.3%) in AR-V7- and AR-V7 + patients, respectively (p = 0.03; Fisher’s exact test).

Back to article page